Top Medical News
Audrey Abella, Yesterday
A single dose of the human glucagon receptor (GCGR) antibody, REMD-477, reduces the amount of insulin necessary and significantly improves glycaemic control in individuals with type 1 diabetes (T1D), according to a study presented at the ADA 2017 in San Diego, California, US.
Yesterday
Circulating glucagon-like peptide 1 (GLP-1) levels increase with chronic and acute inflammatory processes like sepsis and chronic kidney disease, a recent study has found.
Elaine Soliven, Yesterday
Severe obesity in children and adolescents may increase the risk of developing youth-onset diabetes, according to a study presented at the American Diabetes Association’s 77th Scientific Sessions held in San Diego, California, US.
Roshini Claire Anthony, Yesterday

Insulin degludec had comparable cardiovascular safety and reduced the risk of severe hypoglycaemia compared with insulin glargine U100 in patients with type 2 diabetes and high cardiovascular risk, according to results of the DEVOTE* study.

Yesterday
Glycated haemoglobin (HbA1c) is a predictor of major adverse cardiac events (MACEs) in nondiabetic individuals after acute myocardial infarction (AMI), a new retrospective observational study reports.
Yesterday
Podcast: Dr Steven Marso speaks about the cardiovascular safety of insulin degludec vs insulin glargine in patients with type 2 diabetes with high cardiovascular risk.
Yesterday
Podcast: Professor Robert Henry talks about the effects of alirocumab vs usual care in patients with type 2 diabetes and mixed dyslipidemia.
Special Reports
05 Apr 2017
At a recent lunch symposium held in conjunction with the 1st Malaysian Advances in Women’s Health Congress 2016, Professor Dr Jamiyah Hassan imparted clinical updates and strategies for the optimization of hormone replacement therapy in menopausal women. Highlights from her presentation are summarized below.
16 Mar 2017
Recently, Dr Peter Lin of the Canadian Heart Research Centre spoke on treatment strategies in the management of dyslipidaemia and T2DM at an AstraZeneca-sponsored continuing medical education event. Highlights of his presentations are summarized below.
20 Jan 2017
At the recent Malaysian Osteoporosis Society 2016 Clinical Practice Guideline (CPG) Meeting held on the 8th of October 2016 at Ibis Styles Ipoh, Dr Hew Fen Lee and Professor Dr Chan Siew Pheng presented clinical guidance on the management of osteoporosis, and discussed whether the benefits of treatment outweigh the risks.
04 Jan 2017
At the Diabetes Asia 2016 Conference organized by the National Diabetes Institute, Professor Jean Claude Mbanya presented the case for why gliclazide modified release (MR; Diamicron® MR, Servier) should be the treatment of choice for early and aggressive control of type 2 diabetes (T2D).
16 Dec 2016
BASALOG – Insulin glargine (rDNA) 100 IU/mL soln for inj (cartridge) – CCM Pharmaceuticals
16 Dec 2016
INVOKANA – Canagliflozin hemihydrate 100 mg and 300 mg FC tab – Johnson & Johnson (Janssen)
Pearl Toh, 07 Dec 2016
Preventing hypertension, diabetes, and obesity, which are the major risk factors for heart failure (HF), by ages 45 and 55 years may lower risks of incident HF and prolong HF-free survival, suggests data from the Cardiovascular Disease Lifetime Risk Pooling Project.
Conference Reports
Audrey Abella, 22 Jun 2017
A single dose of the human glucagon receptor (GCGR) antibody, REMD-477, reduces the amount of insulin necessary and significantly improves glycaemic control in individuals with type 1 diabetes (T1D), according to a study presented at the ADA 2017 in San Diego, California, US.
Elaine Soliven, 22 Jun 2017
Severe obesity in children and adolescents may increase the risk of developing youth-onset diabetes, according to a study presented at the American Diabetes Association’s 77th Scientific Sessions held in San Diego, California, US.
Roshini Claire Anthony, 21 Jun 2017

Insulin degludec had comparable cardiovascular safety and reduced the risk of severe hypoglycaemia compared with insulin glargine U100 in patients with type 2 diabetes and high cardiovascular risk, according to results of the DEVOTE* study.

21 Jun 2017
Podcast: Dr Steven Marso speaks about the cardiovascular safety of insulin degludec vs insulin glargine in patients with type 2 diabetes with high cardiovascular risk.
21 Jun 2017
Podcast: Professor Robert Henry talks about the effects of alirocumab vs usual care in patients with type 2 diabetes and mixed dyslipidemia.
21 Jun 2017
Podcast: Professor Bruce Neal summarizes the key findings of the Canagliflozin Cardiovascular Assessment Study.
21 Jun 2017
Podcast: Dr Carla Greenbaum speaks about the potential clinical impact of identifying individuals at risk of type 1 diabetes.
CME Modules
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
DOWNLOAD